title: [Comorbidity in rheumatoid arthritis].
abstract: Patients with rheumatoid arthritis (RA) often have one or more comorbid conditions. The prevalence of comorbidities increases with age and disease duration. Comorbidities influence the outcome of RA and limit therapeutic options. Besides suppressing disease activity of RA, screening and tight control of existing comorbidities is essential to avoid further damage. A close cooperation between general practitioners, rheumatologists and attending specialists is important for a successful treatment, taking into account the complex interaction of RA and its comorbidities.
authors.affiliation: Deutsches Rheuma-Forschungszentrum Berlin.
authors.forename: K
authors.initials: K
authors.lastname: Albrecht
mesh_terms: D000203:Activities of Daily Living / Q000145:classification; D000367:Age Factors; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000453:epidemiology*; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use; D015897:Comorbidity; D003327:Coronary Disease / Q000453:epidemiology; D017281:Cost of Illness; D003920:Diabetes Mellitus / Q000453:epidemiology; D004185:Disability Evaluation; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000453:epidemiology; D011788:Quality of Life; D012307:Risk Factors; D012737:Sex Factors; D013959:Thyroid Diseases / Q000453:epidemiology
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products